Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BioAtla, Inc. Director's Dealing 2020

Dec 15, 2020

34681_dirs_2020-12-15_f862b3f0-1430-46ac-ac9e-b1c24635fc98.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: BioAtla, Inc. (BCAB)
CIK: 0001826892
Period of Report: 2020-12-15

Reporting Person: Cormorant Asset Management, LP (10% Owner)
Reporting Person: Chen Bihua (Director, 10% Owner)
Reporting Person: Cormorant Global Healthcare Master Fund, LP (10% Owner)
Reporting Person: Cormorant Private Healthcare Fund II, LP (10% Owner)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Series D Convertible Preferred Stock $ Common Stock (1492060) Indirect

Footnotes

F1: Shares of Series D Convertible Preferred Stock are convertible at any time at the holder's election, without payment of additional consideration. Such shares have no expiration date but are expected to convert into Common Stock automatically upon the closing of the Issuer's initial public offering.

F2: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund II, LP ("Fund II"). Cormorant Global Healthcare GP, LLC ("GP LLC") and Cormorant Private Healthcare GP II, LLC ("GP II") serve as General Partner of the Master Fund and Fund II, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP II. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 3 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F3: Shares of Series D Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 310,945 shares held by the Master Fund and (ii) 1,181,115 shares held by Fund II.